Aptorum Group Limited Total Assets 2011-2026 | APM

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Aptorum Group Limited

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
18.7 M	16.1 M	20.6 M	20.9 M	21.9 M	44.2 M	24 M	45.1 M	31.6 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
45.1 M	16.1 M	27 M

Quarterly Total Assets Aptorum Group Limited

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	21.9 M	-	31.7 M	-	44.2 M	-	23.3 M	-	24 M	-	-	-	45.1 M	-	-	-	31.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
45.1 M	21.9 M	31.7 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	2.03 B	-	2.43 %	$ 254 M	Germany
AgeX Therapeutics AGE	6.95 M	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	6.33 B	-	-	$ 866 M	China
Esperion Therapeutics ESPR	466 M	$ 3.13	0.55 %	$ 651 M	USA
Exelixis EXEL	2.84 B	$ 48.2	8.51 %	$ 13.1 B	USA
Midatech Pharma plc MTP	18.2 M	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	18.1 B	-	-	$ 40.3 B	USA
Fortress Biotech FBIO	186 M	$ 2.53	2.85 %	$ 70.6 M	USA
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Genfit SA GNFT	151 M	-	2.54 %	$ 160 B	France
EyeGate Pharmaceuticals, Inc. EYEG	15.2 M	-	-1.52 %	$ 24.7 M	USA
Galapagos NV GLPG	3.41 B	$ 28.81	1.48 %	$ 2.69 B	Belgium
Athira Pharma ATHA	92.2 M	-	-	$ 269 M	USA
Genmab A/S GMAB	21.1 B	$ 27.95	1.5 %	$ 17.2 B	Danmark
Genprex GNPX	10.2 M	$ 0.91	2.24 %	$ 849 K	USA
Grifols, S.A. GRFS	21.4 B	$ 8.4	1.63 %	$ 6.83 B	Spain
InflaRx N.V. IFRX	55.2 M	$ 2.51	27.16 %	$ 152 M	Germany
Ionis Pharmaceuticals IONS	3.52 B	$ 77.0	2.33 %	$ 12.3 B	USA
BioNTech SE BNTX	22 B	$ 94.64	-0.9 %	$ 27.2 B	Germany
Kamada Ltd. KMDA	379 M	$ 8.29	0.91 %	$ 260 M	Israel
Институт стволовых клеток человека ISKJ	1.51 B	-	-	-	Russia
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
Kymera Therapeutics KYMR	1.74 B	$ 85.79	3.72 %	$ 7.25 B	USA
Kazia Therapeutics Limited KZIA	35 M	$ 13.58	0.97 %	$ 1.8 B	Australia
Ligand Pharmaceuticals Incorporated LGND	942 M	$ 231.58	-0.31 %	$ 4.24 B	USA
INmune Bio INMB	32.4 M	$ 1.54	-	$ 38.1 M	USA
Liquidia Corporation LQDA	328 M	$ 41.64	3.75 %	$ 3.58 B	USA
ACADIA Pharmaceuticals ACAD	1.19 B	$ 22.58	1.03 %	$ 3.74 B	USA
Mirum Pharmaceuticals MIRM	843 M	$ 107.36	1.46 %	$ 5.39 B	USA
MannKind Corporation MNKD	792 M	$ 3.61	26.17 %	$ 1.1 B	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 3.46	-1.14 %	$ 5.7 M	Israel
Aeterna Zentaris AEZS	21.4 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	778 M	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	1.16 B	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	66.7 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	113 M	-	1.93 %	$ 17.4 M	USA
Akero Therapeutics AKRO	826 M	-	-	$ 3.67 B	USA
Aptose Biosciences APTO	10 M	-	-45.71 %	$ 1.2 M	Canada
Aptinyx APTX	66.7 M	-	-39.0 %	$ 4.57 M	USA
Akouos AKUS	279 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	302 M	-	-0.23 %	$ 916 M	USA
Allakos ALLK	244 M	-	-	$ 28.6 M	USA
AlloVir ALVR	122 M	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	433 M	$ 24.0	2.46 %	$ 3.05 B	USA
Nanobiotix S.A. NBTX	67.8 M	$ 41.6	19.64 %	$ 286 B	France
Allena Pharmaceuticals ALNA	34.8 M	-	3.16 %	$ 1.9 M	USA
Ampio Pharmaceuticals AMPE	5.74 M	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	107 M	-	-	$ 10.1 M	USA
Alpine Immune Sciences ALPN	287 M	-	-	$ 2.17 B	USA